<DOC>
	<DOC>NCT02825940</DOC>
	<brief_summary>This phase I, open-label, multicenter study will evaluate the pharmacokinetics, safety, and preliminary anti-tumor activity of atezolizumab in Chinese participants with locally advanced or metastatic gastric cancer, nasopharyngeal cancer, esophageal cancer, hepatocellular carcinoma (HCC), and other solid tumor types that are refractory to standard therapeutic modalities and for whom no further standard therapy is available or who have refused standard therapy.</brief_summary>
	<brief_title>A Study to Assess Pharmacokinetics and Safety of Atezolizumab Administered Intravenously to Chinese Participants With Locally Advanced or Metastatic Solid Tumors (IMYO29233)</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically documented, incurable or metastatic solid tumor that is advanced (nonresectable) or recurrent and progressing since the last the antitumor therapy and for which no recognized standard curative therapy exists or who have refused the standard therapy Adequate hematologic and end organ function Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or modified Response Evaluation Criteria in Solid Tumors (mRECIST) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Women who are not postmenopausal (greater than or equal to [&gt;/=] 12 months of nontherapyinduced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment Women of childbearing potential must agree to remain abstinent or use contraceptive methods specified in the study For enrollment into the China extension cohort, residence in the People's Republic of China Any approved anticancer therapy, including chemotherapy, targeted therapy or hormonal therapy less than (&lt;) 5 halflives prior to initiation of study treatment Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment Uncontrolled hypercalcemia (greater than [&gt;] 1.5 millimol per liter [mmol/L] ionized calcium or calcium &gt;12 milligram per deciliter (mg/dL) or corrected serum calcium greater than the upper limit of normal [ULN]) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis, cirrhosis, fatty liver, and inherited liver disease Participants with acute leukemia, accelerated/blastphase chronic myelogenous leukemia, chronic lymphocytic leukemia, Burkitt lymphoma, plasma cell leukemia, or nonsecretory myeloma Active or untreated central nervous system (CNS) metastases as determined by computed tomography or magnetic resonance imaging evaluation during screening and prior radiographic assessments Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications History of human immunodeficiency virus, hepatitis B (except the HCC cohort), or hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>